Conference Videos

Tumor Immunotherapy Symposium: A Clinical Perspective | November 18, 2016

The Tumor Immunotherapy Symposium: A Clinical Perspective was a key educational event organized by the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. For our inaugural Symposium, our objective was to provide a clinical and translational perspective on tumor immunotherapy by highlighting the current and upcoming clinical trials being conducted in this field in Toronto as well as exciting emerging therapies worldwide. Participants learned the current status of clinical trials involving immune checkpoint inhibitors, adoptive cell therapy and oncolytic viruses as well as case-based discussion on the assessment and management of immune related adverse events.

This one-day symposium was held at the MaRS Discovery District in downtown Toronto on November 18, 2016.

Introduction and KEYNOTE: Harnessing the Immune System to Treat Cancer

Dr. Mario Sznol, MD, Yale Cancer Center

Immune Checkpoint Inhibitors and Co-Stimulatory Molecules: Targeting Beyond PD- 1/PD-L1

Dr. Philippe Bedard, MD, Princess Margaret Cancer Centre

Update on Princess Margaret Investigator-Initiated Trials: INSPIRE and METADUR

Dr. Anna Spreafico, MD, Princess Margaret Cancer Centre

Predictive Biomarker Evaluations and Immunophenotyping in Tumor Immunotherapy

Dr. Derek Clouthier, PhD, Princess Margaret Cancer Centre

Panel Discussion #1

Dr. Lillian Siu, Dr. Mario Sznol, Dr. Philippe Bedard, Dr. Anna Spreafico & Dr. Derek Clouthier

Adoptive Cell Therapy

Dr. Marcus Butler, MD, Princess Margaret Cancer Centre

Engineering T Cells in Cancer Therapy: CAR-T, TCR-T and Others

Dr. Naoto Hirano, MD, PhD, Princess Margaret Cancer Centre

T Cell Engager Antibodies – with focus on Hematological Malignancies

Dr. John Kuruvilla, MD, Princess Margaret Cancer Centre

Oncolytic viruses

Dr. Guy Ungerechts, MD, PhD, The Ottawa Hospital Cancer Centre

Panel Dicussion #2

Dr. Marcus Butler, Dr. Naoto Hirano, Dr. John Kuruvilla and Dr. Guy Ungerechts

The Status of PD-L1 Testing and What is Next?

Dr. Ming Tsao, MD, Princess Margaret Cancer Centre

Case-Based Presentations

Dr. Aaron Hansen, Dr. Theepa Sundaralingam & Dr. Parneet Cheema